These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 8346727)

  • 21. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
    Campbell RW; Furniss SS
    Am J Cardiol; 1993 Aug; 72(4):80A-85A. PubMed ID: 8346732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
    Hohnloser SH; Singh BN
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New anti-arrhythmia agents].
    Honerjäger P; Schmidt G
    Z Kardiol; 1992; 81 Suppl 4():133-7. PubMed ID: 1363260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
    Boriani G; Lubinski A; Capucci A; Niederle R; Kornacewicz-Jack Z; Wnuk-Wojnar AM; Borggrefe M; Brachmann J; Biffi M; Butrous GS;
    Eur Heart J; 2001 Dec; 22(23):2180-91. PubMed ID: 11913480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
    JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
    Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ
    J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group.
    Hohnloser SH; Meinertz T; Stubbs P; Crijns HJ; Blanc JJ; Rizzon P; Cheuvart B
    Circulation; 1995 Sep; 92(6):1517-25. PubMed ID: 7664435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
    Antz M; Cappato R; Kuck KH
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group.
    Eur Heart J; 1989 Aug; 10(8):685-94. PubMed ID: 2676535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sotalol in treatment of pediatric cardiac arrhythmias.
    Celiker A; Ayabakan C; Ozer S; Ozme S
    Pediatr Int; 2001 Dec; 43(6):624-30. PubMed ID: 11737739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced post-repolarization refractoriness as an antiarrhythmic principle and its underlying mechanism.
    Franz MR; Gray RA; Karasik P; Moore HJ; Singh SN
    Europace; 2014 Nov; 16 Suppl 4():iv39-iv45. PubMed ID: 25362169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias.
    Gonzalez R; Scheinman MM; Herre JM; Griffin JC; Sauve MJ; Sharkey H
    J Am Coll Cardiol; 1988 Dec; 12(6):1568-72. PubMed ID: 3192854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
    Hohnloser SH; van de Loo A; Baedeker F
    J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with sotalol in the treatment of cardiac arrhythmias.
    Kirschenbaum HL; Rosenberg JM
    Clin Ther; 1994; 16(3):346-64. PubMed ID: 7923303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.
    Singh BN
    Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
    Haverkamp W; Eckardt L; Borggrefe M; Breithardt G
    Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antiarrhythmic effects of d-sotalol.
    Schwartz J; Crocker K; Wynn J; Somberg JC
    Am Heart J; 1987 Sep; 114(3):539-44. PubMed ID: 3630894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.
    Kehoe RF; Zheutlin TA; Dunnington CS; Mattioni TA; Yu G; Spangenberg RB
    Am J Cardiol; 1990 Jan; 65(2):58A-64A; discussion 65A-66A. PubMed ID: 2294689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.